Article
AAN: AstraZeneca touts new Ultomiris gMG data ahead of potential Argenx showdown
Rating:
0.0
Views:
82
Likes:
1
Library:
1
When Argenx's Vyvgart won FDA approval in December for generalized myasthenia gravis (gMG), the entrant presented an attractive alternative to AstraZeneca's entrenched rare-disease blockbuster Soli | Tuesday at the American Academy of Neurology (AAN), AstraZeneca presented follow-up results from a phase 3 trial that enhance Ultomiris' chance for approval for generalized myasthenia gravis (gMG). With Soliris and Ultomiris, AZ is battling Argenx's newly approved Vyvgart in gMG.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value